Less data now, as industry wins breathing space over EU product database
This article was originally published in Scrip
Following strong lobbying by the pharmaceutical industry, the European Medicines Agency has substantially reduced the amount of information that companies must provide by 2 July on all the products they market in the EU. Industry will be relieved at the move, having pushed hard for a delay to the deadline or at least a reduction in the scope of the requirement.
You may also be interested in...
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.